Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Franklin Biotechnology Discovery A (acc) USD

Ranked 1 out of 1 in - Biotechnology over 12 months
All calculations are in ZAR unless stated

Managed by

Steven Kornfeld

Steven Kornfeld graduated from the Wharton School of Business at the University of Pennsylvania and Northwestern University’s Kellogg Graduate School of Management and holds a BA in business and an MBA. He has been managing funds for over ten years and is currently a fund manager at Franklin Templeton where he runs US equities. Before this he worked in private equity and previously as a sell-side research analyst where he specialised in emerging growth companies. Steven is a CFA Charterholder.

Evan McCulloch

Evan McCulloch joined Franklin Templeton Investments as a management trainee in 1992. Now a vice president and portfolio manager for the group, McCulloch’s responsibilities include managing the Franklin Biotechnology Fund. A self described research driven investor, McCulloch specialises in research analysis of the health care industry; including pharmaceuticals, health care information systems/internet and health care providers. He is a bottom-up investor who pursues a growth strategy and focuses primarily on individual securities, choosing companies he believes are positioned for rapid growth in revenues, earnings or assets. Born in Mesa, Arizona in 1969, McCulloch graduated from the University of California at Berkeley with a bachelor’s degree in economics and business administration.

Objective

The Fund's investment objective is capital appreciation. The Fund invests principally in equity securities of biotechnology companies and discovery research firms (including small to mid-sized companies) located in the US and other countries, and to a lesser extent in debt securities of any type of issuers worldwide.

Showing fund performance in South Africa View performance globally

Performance

Biotechnology over : 31/07/2016 - 31/07/2017
  • Rank 1/1 Total Return
  • Rank 1/1 Standard Deviation
  • Rank 1/1 Max Drawdown

Total Return

Quarterly Performance

to 30/06/2017 Annual Q1 Q2 Q3 Q4
2017 10.0% -0.5%
2016 -27.5% -28.2% 1.1% 7.1% -6.9%
2015 40.6% 19.5% 4.4% -8.4% 23.0%
2014 48.8% 7.9% 4.2% 16.1% 14.0%
2013 102.8% 28.3% 17.0% 25.2% 8.0%
2012 33.3% 10.4% 15.6% 6.9% -2.3%
2011 33.8% 7.1% 7.2% 3.0% 13.1%
2010 5.7% 9.8% -9.6% 3.4% 2.9%
2009 -11.7% 1.6% -15.8% 7.5% -4.0%
2008 23.7% 9.5% 1.8% 11.0% 0.0%
2007 -5.2% 1.5% 1.0% 1.4% -8.7%
2006 15.4% 3.7% 0.5% 10.6% 0.2%
2005 16.5% -7.6% 18.7% 6.4% -0.2%
2004 -6.7% 1.2% -1.1% 3.1% -9.6%
2003 11.3% -6.5% 17.4% -0.2% 1.6%
2002 -58.7% -19.5% -35.4% -6.9% -14.6%
2001 27.0% -26.3% 24.2% -13.5% 60.3%
2000 20.0% -15.5%

Month by Month Performance

Returns Vs Risk

Asset Allocation

Breakdown

30/06/2017

Top 10 Holdings

Stock Size
Celgene Corp ORD 9.69
Alexion Pharmaceuticals Inc ORD 7.67
Incyte Corp ORD 5.88
Regeneron Pharmaceuticals Inc ORD 5.56
Biogen Inc ORD 4.75
Gilead Sciences Inc ORD 4.50
Illumina Inc ORD 4.14
Clovis Oncology Inc ORD 4.02
Vertex Pharmaceuticals Inc ORD 3.63
TESARO Inc ORD 3.52
30/06/2017

Registered For Sale In

  1. Austria
  2. Belgium
  3. Cyprus
  4. Czech Republic
  5. Denmark
  6. Estonia
  7. Finland
  8. France
  9. Germany
  10. Gibraltar
  11. Greece
  12. Guernsey
  13. Hong Kong
  14. Hungary
  15. Ireland
  16. Italy
  17. Jersey
  18. Korea
  19. Latvia
  20. Lithuania
  21. Luxembourg
  22. Macau
  23. Netherlands
  24. Norway
  25. Peru
  26. Poland
  27. Portugal
  28. Singapore
  29. Slovakia
  30. South Africa
  31. Spain
  32. Sweden
  33. Switzerland
  34. Taiwan
  35. United Kingdom

Fund Info

  • Launch date03/04/2000
  • Share Class size2,071Mn
  • Base currencyUSD
  • ISIN LU0109394709

Purchase Info

  • Min. initial investment5,000
  • Min. regular additional investment0

Charges

  • Annual management1.00%
  • Initial investment5.75

Related News

Franklin Templeton boosts blockbuster biotech team

US giant assigns third person to oversee dedicated equity investment vehicle, Citywire Selector learns.

Politics will not 'kill the golden goose', says biotech specialist

Franklin Templeton's Evan McCulloch is braced for potential disruption from Presidential race but believes idiosyncratic stories can stand up to the task.

Franklin Templeton reopens blockbuster biotech fund

US giant ends soft-close measures after 18-months following fall in assets under management and market correction.

Biotech manager departs Franklin Templeton

Sector specialist ends three-year stint on soft-closed strategy with pharma expert named as replacement, Citywire Global has learned.

Biotech equity’s most consistent managers of the past five years

Citywire Global uncovers the pair of sector specialists continually staying ahead of the average peer over the past half-decade.

Bright lights in biotech: two most consistent managers revealed

The specialist health care sector has received increased interest over the past five years but only two managers have regularly beaten the average manager.

Franklin Templeton soft-closes star European manager's €3bn fund

The fund co-managed by a Citywire AA-rated manager has seen its assets rise €600 million over the last six months, Citywire Global can reveal.

Franklin Templeton to soft-close blockbuster biotech fund

US asset manager announces plans to stem flows into dedicated strategy as interest in sector rises, Citywire Global has learned.

This isn’t a bubble, it’s an R&D boom, says top biotech manager

Despite rapid multiple expansion, the fundamentals are solid, says Franklin Templeton’s Evan McCulloch.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).